<DOC>
	<DOC>NCT00889863</DOC>
	<brief_summary>This two-part study assessed the sustained efficacy of canakinumab in the double-blind Part II and the ability to taper steroids in the open label Part I.</brief_summary>
	<brief_title>Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Juvenile</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Confirmed diagnosis of systemic juvenile idiopathic arthritis as per International League Against Rheumatism (ILAR) definition that must have occurred at least 2 months prior to enrollment with onset of disease &lt; 16 years of age. Arthritis in one or more joints with or preceded by fever of at least 2 weeks duration that is documented to be daily for at least 3 days with accompanying symptoms Active disease at the time of enrollment defined as follows: At least 2 joints with active arthritis (using American College of rheumatology) ACR definition of active joint) Documented spiking, intermittent fever (body temperature &gt; 38oC) for at least 1 day during the screening period within 1 week before first study drug dose Creactive protein &gt; 30 mg/L (normal range &lt; 10 mg/L) No concomitant use of second line agents such as diseasemodifying and/ or immunosuppressive drugs will be allowed with the exception of: Stable dose of methotrexate for at least 8 weeks prior to the screening visit, and/or folic/folinic acid per standard medical practice Stable dose of no more than one nonsteroidal antiinflammatory drug for at least 2 weeks prior to the screening visit Stable dose of steroid treatment &lt; or = to 1.0 mg/kg/day in 12 doses per day of oral prednisone or equivalent Exclusion criteria: Diagnosis of active macrophageactivation syndrome (MAS) within the last 6 months Risk factors for tuberculosis Patients with active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of HIV infection, Hepatitis B and Hepatitis C infection Other protocol inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Flare</keyword>
	<keyword>arthritis</keyword>
	<keyword>IL-1beta antagonist</keyword>
	<keyword>systemic juvenile idiopathic arthritis</keyword>
	<keyword>Juvenile rheumatoid</keyword>
</DOC>